We examine the immunoreactivity of the non-receptor tyrosine kinase, c-Src kinase and its downstream molecule, signal transducer and activator of transcription 3 (pStat3) in retinoblastoma (RB), and correlation with invasiveness and differentiation. Tumor samples from 40 patients with RB were available for the study. There were 18 tumors in group 1 (non-invasive) and 22 tumors in group 2 (invasive). The immunoreactivity of c-Src kinase and pStat3 was compared in the two groups of tumors. Group 1 (non-invasive) RB showed intermediate c-Src kinase immunoreactivity (Allred score 4-5) in 14/18 tumors and low immunoreactivity (Allred score 2-3) in 4/18 tumors. pStat3 was intermediate (Allred score 4-5) in 6/18 tumors and negative (Allred score 0) in 12/18 tumors. Group 2 (invasive) RB showed high c-Src kinase immunoreactivity (Allred score 6-8) in 22/22 tumors and high pStat3 (Allred score 6-8) in 19/22 tumors. The expression of c-Src kinase (P<0.001) and pStat3 (P<0.001) was significantly higher in group 2 RB. Src kinase expression (P<0.05) and pStat3 expression (P<0.05) was higher in the poorly differentiated tumors compared to moderately- and well-differentiated tumors. The increased expression of c-Src kinase and pStat3 expression could play a role in the invasiveness of group 2 tumors. Further characterization of the pathways involved in the pathogenesis of RB will shed light on fundamental mechanisms of tumorigenesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.exer.2006.02.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Csk controls leukocyte extravasation via local regulation of Src family kinases and cortactin signaling.
Front Immunol
November 2024
Department of Vascular Cell Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany.
C-terminal Src kinase (Csk) targets Src family kinases (SFKs) and thereby inactivates them. We have previously shown that Csk binds to phosphorylated tyrosine 685 of VE-cadherin, an adhesion molecule of major importance for the regulation of endothelial junctions. This tyrosine residue is an SFK target, and its mutation (VE-cadherin-Y685F) inhibits the induction of vascular permeability in various inflammation models.
View Article and Find Full Text PDFRecent advances of small-molecule c-Src inhibitors for potential therapeutic utilities.
Bioorg Chem
October 2023
School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address:
Article Synopsis
- Proto-oncogene tyrosine-protein kinase Src (c-Src) is a key player in cell processes like division and survival, affecting both healthy and cancerous cells through various signaling pathways.
- There is a strong link between c-Src and bone-related diseases, such as osteoporosis, because of its role in osteoclasts and inflammation.
- Recent efforts have led to the development of c-Src inhibitors, with a review highlighting advances in their mechanisms, drug discovery, combination therapies, and ongoing clinical research to inspire further innovation in treatment options.
Focal Adhesion Kinase (FAK) and c-Src Dependent Signal Transduction in Cell Adhesion.
Discov Med
October 2024
Laboratory of Human Anatomy and Cell Biology, Faculty of Health Sciences, Tsukuba University of Technology, 305-8521 Tsukuba, Japan.
This review predominantly acquaints the role of focal adhesion kinase (FAK) and cellular-Src (c-Src) in cell adhesion. Cell adhesion is a crucial phenomenon that causes the cells to interact with the extracellular matrix (ECM) or with each other. There are different proteins involved in cell adhesion including cell adhesion molecules (CAMs)/receptors that are present on the cell surface and various cytoplasmic proteins.
View Article and Find Full Text PDFStructural Basis for Long Residence Time c-Src Antagonist: Insights from Molecular Dynamics Simulations.
Int J Mol Sci
September 2024
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China.
Article Synopsis
- c-Src plays a crucial role in various cancer signaling pathways and is a key target for cancer treatment.
- Research indicates that extending the residence time of drugs can improve their effectiveness, leading to the development of c-Src antagonists with longer residence times.
- The study utilized molecular dynamics simulations to analyze the binding behavior of different antagonists, identifying a new compound, DFOGS, that enhances binding stability by replacing an unstable amide group, which could lead to better therapeutic outcomes.
Endothelial c-Src Mediates Neovascular Tuft Formation in Oxygen-Induced Retinopathy.
Am J Pathol
December 2024
Centre for Cell Biology of Chronic Disease, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Queensland, Australia. Electronic address:
Vascular retinopathy, characterized by abnormal blood vessel growth in the retina, frequently results in vision impairment or loss. Neovascular tufts, a distinctive pathologic feature of this condition, are highly leaky blood vessel structures, exacerbating secondary complications. Despite their clinical significance, the mechanisms underlying tuft development are not fully elucidated, posing challenges for effective management and treatment of vascular retinopathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!